Innovative drug out-licensing deal value vs Clinical trial registrations in China
In 2025, innovative drug out-licensing deal value in China was 130 billion USD; clinical trial registrations was 5,215.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time in 2025 . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.
Innovative drug out-licensing deal value
Unit: billion USD · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| 2025 | Actual | 130 billion USD |
Clinical trial registrations
Unit: count · 1 observation
View the underlying data
| Period | Type | Value |
|---|---|---|
| 2025 | Actual | 5,215 |
Shared periods
Side by side
Only one period is published for both series in China. Comparing anything else would mean comparing different years.
| Period | Innovative drug out-licensing deal value | Clinical trial registrations |
|---|---|---|
| 2025 | 130 billion USD | 5,215 |
Provenance
Where these numbers come from
Innovative drug out-licensing deal value
Total monetary value of out-licensing agreements signed for innovative pharmaceutical products.
2 observations in China · source organisations: NHSA
Clinical trial registrations
Number of clinical trials registered on the International Clinical Trials Registry Platform.
4 observations in China · source organisations: State Council, NHSA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring